Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse

Next Previous
Trial Profile

Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Estramustine (Primary) ; Aspirin; Bicalutamide; Buserelin; Cyproterone; Flutamide; Goserelin; Leuprorelin; Nilutamide; Prednisone; Triptorelin; Warfarin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GETUG-12

Most Recent Events

  • 17 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 21 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
  • 08 Feb 2019 Results published in the Internet Document

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top